Compare Global X CleanTech (CTEC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Moderna, Inc. — how do they compare? Global X CleanTech trades at $56.36 (market cap $24.57M), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 3201.1× Global X CleanTech's market cap, and Moderna, Inc. is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Moderna, Inc. for 59 Days on average.
| CTEC | MRNA | |
|---|---|---|
Market Cap | $24.57M | $78.65B |
Volume | 1,220 | 37,373,437 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $203.46 |
52-Week Low | $50.82 | $22.36 |
Typical Hold Time | 42 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $56.36, up 0.25% today, with a bullish technical signal from moving averages and strong trend strength (ADX 46.60). The stock faces resistance near $58 and support at $57. Key financial ratios like P/E and P/S are not provided, limiting fundamental clarity.
The outlook hinges on upcoming earnings to validate growth. Risks include opaque financials and market volatility. Analyst sentiment is mixed, with institutional interest needed to confirm the bullish technical setup.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
